LILLY

Disarm® Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company, is pursuing a promising new class of potential therapeutics called SARM1 inhibitors that target axonal degeneration as a treatment for amyotrophic lateral sclerosis (ALS - Lou Gehrig's Disease), multiple sclerosis, peripheral neuropathies - which cause weakness and pain in the feet and hands - and other debilitating neurological disorders... A new class of therapeutics called SARM1 inhibitors is being pursued at Lilly Research Labs which may dramatically delay axonal degeneration, and improve quality of life for patients with neurodegenerative diseases.

Also known as: Disarm® Therapeutics

Primary location: Indianapolis United States